Product Overview
Generic name: Caowujiasu soft capsule
Chinese Pinyin: Caowujiasu Ruanjiaonang
English name: Bulleyaconitine A Soft Capsules
Product name: Guan Wei
Ingredients: The main ingredient of this product is the alkaloid extracted from Aconitum aconitum, a plant of the genus Aconitum in Ranunculaceae.
Properties: The content of this product is light yellow oily liquid.
Indications: For osteoarthritis, rheumatoid arthritis
Specification: 0.4mg
Usage and dosage: Oral. Take 1 capsule (0.4mg) at a time, twice a day, take it with warm water after meals. 30 days is a course of treatment.
Adverse reactions: Anorexia, abdominal distension, tongue numbness, stomach pain, heart palpitations, heartburn in some cases
Contraindications: Use with caution in patients with heart disease.
Note: Please keep this product out of the reach of children; if there is an adverse reaction, please stop the drug and take an appropriate amount of honey (50-100g). In severe cases, send it to the hospital for corresponding treatment.
Drug interactions: The experiment has not been conducted and there is no reliable reference data
Pharmacology and Toxicology: 1. Pharmacological effects
Aconitine is a diterpene ester alkaloid extracted from Aconitum aconitum, a plant of the genus Aconitum in Ranunculaceae, Yunnan. It has a strong analgesic effect and an anti-inflammatory effect.
2. Toxicological research
Aconitum A has a greater acute toxicity. The median lethal dose (LD50) of intragastric administration in mice is 8.44 mg/kg (2.9 mg/kg has been reported in the literature); relevant animal toxicology literature suggests that the LD50 The toxicity of the diester alkaloids is mainly to stimulate the nervous system (especially the vagus nerve and sensory nerve), first excites and then inhibits, and has a direct effect on the myocardium (mainly manifested in clinical arrhythmia, and the electrocardiogram is supraventricular and ventricular) Extrasystole, atrioventricular block, ST-segment changes, etc.), may die from breathing or myocardial palsy.
Pharmacokinetics: 1. This product has not been studied in human pharmacokinetics. After intravenous injection of aconitine A in rats, the blood drug-time curve shows an open three-compartment model, and the half-lives of the three phases are fast distribution phases. Half-life = 2.87 minutes, distribution phase half-life = 11.6 minutes, elimination phase half-life = 5 hours.
2. The tissue distribution is highest in liver and adrenal glands, followed by kidney, lung, spleen and heart. Brain content is lower, while brain stem content is higher than cortex.
3. After 4 hours of administration, the content in each organ was reduced by 50%. Within 6 days after administration, the amount of urine excretion accounted for 46% of the intake, and the most excreted within 21 hours was 82.3 of the total urine excretion. %, the excretion from feces within 6 days accounted for 21.9% of the intake, and the excretion from feces within 48 hours accounted for 86.2% of the total excretion from feces.
Overdose: Strictly control the dosage, do not use more than 2 times a day, and do not exceed one capsule (0.4mg) each time; once adverse reactions occur, the medication should be stopped immediately and supportive symptomatic treatment should be adopted.
Storage: Keep away from light and sealed.
Packing: Aluminum-plastic blister pack, 10 tablets per board, 1 board per box.
Validity period: 30 months
Approval number: National Medicine Zhunzi H20031060
Company Name: Kunyao Group Co., Ltd.
